Please select the option that best describes you:
For what patients/diagnoses do you currently use sodium thiosulfate to reduce the risk of cisplatin associated ototoxicity?
STS was approved in 2022 in the US to reduce risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic tumors. Have you expanded to using in other populations?
Answer from: at Academic Institution
Sodium thiosulfate (STS) is approved in the US (FDA) and Europe (EMA) for the prevention of cisplatin-induced hearing loss (CIHL) in patients 1 month and older treated with cisplatin for any type of cancer. Although intravenous STS has not been subjected to a randomized clinical trial for patients &...
Sign in or Register to read more